Drug interactions in cancer patients: A hidden risk?
نویسندگان
1 Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, University of Sao Paulo, São Paulo, Brazil
2 Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, University of Sao Paulo, São Paulo, Brazil
doi
10.4103/2279-042X.179560چکیده
Drug combinations with the potential to interact comprise an important but rather neglected topic in clinical cancer research. While several studies have evaluated drug interactions in general medicine, and the potential risks for patient’s safety are well discussed, only few have addressed this subject in patients with cancer. Given the often large, andfrequently increasing, number of drugs that cancer patients take, drug–drug interactions (DDIs) may pose a real threat of undesired adverse events, of increased or decreased efficacy of antineoplastic agents and may ultimately impact on patients’ quality of life.
